NCT01239628
Terminated
Not Applicable
A National, Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities up to 3 Years Follow up of Botulinum Toxin A in Adult Subjects Suffering From Upper Limb Spasticity Post-CVA (Cerebrovascular Accident)
ConditionsUpper Limb Spasticity After Stroke
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Upper Limb Spasticity After Stroke
- Sponsor
- Ipsen
- Enrollment
- 45
- Locations
- 11
- Primary Endpoint
- Documentation of the injection intervals
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject able to comply with the protocol
- •Provision of written informed consent prior to collecting the data
- •Male or female patients of 18 years or older
- •Presenting with upper limb spasticity after stroke for which treatment with botulinum toxin A is indicated
Exclusion Criteria
- •The subject has already been included in this survey
- •Patients who already received BoNT-A treatment for upper limb spasticity
- •Patients with known intolerance for BoNT-A
- •Subjects unable to comply with the protocol
Outcomes
Primary Outcomes
Documentation of the injection intervals
Time Frame: 3 years
Documentation of treatment modalities
Time Frame: 3 years
Secondary Outcomes
- Documentation of the main reason(s) for dose change(s)(3 years)
- Documentation of the main reason(s) for change in injection intervals(3 years)
- Documentation of the physician satisfaction with the treatment(3 years)
- Documentation of the patient satisfaction with the treatment(3 years)
Study Sites (11)
Loading locations...
Similar Trials
Completed
Not Applicable
Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGOHemophilia ANCT01959919Pfizer86
Completed
Not Applicable
Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)EpilepsyNCT01532726Bial - Portela C S.A.56
Unknown
Not Applicable
A Study to Prospectively Assess Disease Progression in Male Children With X-ALDX-Linked AdrenoleukodystrophyNCT03278899NeuroVia, Inc.100
Terminated
Not Applicable
Predictive Factors StudyAcromegalyNCT02020499Ipsen5
Completed
Not Applicable
Retrospective Observational Study DIANA StudyMajor Depressive EpisodeNCT01976793AstraZeneca450